GeneDx COO Dechairo sells $510k in WGS stock By Investing.com
GeneDx Holdings Corp.'s COO, Bryan Dechairo, sold 6,061 shares of Class A Common Stock for over $510,000 on February 4, 2026, as part of a pre-arranged trading plan. This transaction leaves him with zero direct shares, occurring amidst recent stock volatility. Despite the sales, analysts maintain optimistic price targets for GeneDx, which projects significant revenue growth for 2026 and has announced new strategic partnerships and product launches.
GeneDx COO Dechairo sells $510k in WGS stock
GeneDx Holdings Corp. COO Bryan Dechairo sold 6,061 shares of Class A Common Stock for over $510,000 on February 4, 2026, as part of a pre-arranged trading plan, leaving him with no direct ownership. Despite a recent stock decline, analysts remain optimistic about WGS, with price targets ranging from $153 to $200. The company anticipates strong revenue growth for 2025 and 2026, is launching a new prenatal test, and has appointed a new Chief Medical Officer.
Surging AI-Driven Genetic Testing Demand Might Change The Case For Investing In GeneDx Holdings (WGS)
GeneDx Holdings (WGS) recently reported strong revenue growth of 51.90%, driven by increasing demand for its AI-powered genetic testing services focused on pediatric and rare disease diagnostics. While this growth and FDA Breakthrough status strengthen its investment thesis, significant share price pullback, high sales multiples, and insider selling introduce execution and valuation risks. Despite the optimism, investors hold widely divergent fair value estimates, emphasizing the importance of comprehensive research beyond the headlines.
GeneDx Holdings Corp. (NASDAQ:WGS) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
GeneDx Holdings Corp.'s shares dropped 29% over the past month, though the stock still shows a 34% gain over the last year. Despite the recent dip, the company maintains a high price-to-sales ratio of 7.2x, significantly above the industry average, driven by strong revenue growth of 51% last year and a forecast of 22% annual growth for the next three years. This anticipated strong performance relative to the Healthcare industry's 6.1% growth appears to be sustaining investor confidence and the elevated P/S ratio.
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. The firm encourages long-term GeneDx shareholders to contact them to explore legal options such as seeking corporate governance reforms, fund recovery, or financial incentives. Halper Sadeh LLC handles actions on a contingent fee basis, and shareholder participation is highlighted as important for improving company policies and enhancing shareholder value.
A Look At GeneDx Holdings (WGS) Valuation After GenomeDx Prenatal Launch And New Chief Medical Officer Appointment
GeneDx Holdings (WGS) has launched GenomeDx Prenatal, a new whole genome sequencing test, and appointed Dr. Linda Genen as Chief Medical Officer. Despite recent stock fluctuations, the company shows strong long-term momentum, trading at a significant discount to analyst price targets and estimated fair value. The article explores the valuation gap and potential factors influencing its future growth and profitability, highlighting both opportunities and challenges.
Should GeneDx’s GUARDIAN Newborn Genomics Accolade Reshape the Investment Narrative for WGS Investors?
GeneDx Holdings Corp. (WGS) received significant recognition for its GUARDIAN newborn genomic screening work, being selected among JAMA’s Research of the Year. This accolade strengthens the investment narrative around broader pediatric and NICU adoption of its genomics platform, however, the company still faces risks related to payer reimbursement and cost containment. GeneDx's narrative projects substantial revenue and earnings growth by 2028, with Simply Wall St's fair value estimate suggesting a 25% upside from its current price.
Is JAMA’s GUARDIAN Nod Quietly Reframing GeneDx (WGS) as a Core Newborn Genomics Platform?
JAMA's recognition of GeneDx's GUARDIAN study highlights the potential of large-scale genomic newborn screening to detect treatable, often-missed childhood conditions and strengthens the clinical case for widespread adoption. While this bolsters GeneDx's investment narrative, the company's long-term success still hinges on broader payer and health system adoption, as well as managing reimbursement and pricing pressures. The FDA Breakthrough Device Designation also supports their efforts to build regulatory-grade evidence for future policy decisions and hospital integration.
News Headline | Today! The Largest Options Expiry in History: Will U.S. Stocks Face a "Wild Day"?
Wall Street is bracing for an unprecedented "triple witching" event with a record-breaking $7.1 trillion in options contracts set to expire, including $5 trillion linked to the S&P 500 Index. This historic expiry could lead to significant market volatility or a "pinning" effect, with analysts closely watching the S&P 500's ability to hold the critical 6,800-point level. The massive volume and potential for dramatic market swings make this a crucial event for year-end market movements.
GeneDx (WGS) Valuation Check as JAMA Highlights GUARDIAN Newborn Genomic Screening Study
GeneDx Holdings (WGS) has seen a significant boost with its GUARDIAN newborn genomic screening study being highlighted in JAMA’s Research of the Year, leading to a 76% year-to-date share price increase. While analysts estimate its fair value in the mid-$160s, suggesting it's undervalued, a Simply Wall St DCF model is even more optimistic, valuing shares around $253.46. Investors are evaluating whether the market is underestimating GeneDx's long-term potential in newborn genomics.
GeneDx Holdings Corp. Executives Sell Shares for Tax Obligations
GeneDx Holdings Corp.'s CEO, Katherine Stueland, and CFO, Kevin Feeley, sold shares to cover tax obligations related to RSU vesting. Stueland sold 10,857 shares for $1,562,185, and Feeley sold 3,855 shares for $554,616. Following these transactions on December 16, 2025, Stueland directly owns 14,237 shares and Feeley directly owns 8,731 shares.
GeneDx Holdings Corp. Executives Sell Shares to Cover Tax Obligations
GeneDx Holdings Corp.'s CEO, Katherine Stueland, and CFO, Kevin Feeley, recently sold shares of Class A Common Stock to cover tax obligations from vested restricted stock units (RSUs). Stueland sold 3,639 shares for $579,619, while Feeley sold 1,266 shares for $201,648, both on December 9, 2025, at $159.28 per share. These sales were solely for tax withholding purposes.
Feeley, GeneDx CFO, sells $61,276 in WGS stock
GeneDx Holdings Corp CFO Kevin Feeley sold 377 shares of Class A Common Stock for $61,276 on December 1, 2025, while also exercising options on 717 shares. This news follows recent Q3 2025 earnings where GeneDx missed EPS expectations but exceeded revenue forecasts and raised its 2025 guidance. Analysts from Guggenheim and BTIG subsequently increased their price targets for GeneDx, maintaining Buy ratings due to strong growth in genetic testing.
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of GeneDx stock to contact them to learn about potential legal rights and options, including seeking corporate governance reforms or financial incentives. Halper Sadeh LLC handles these actions on a contingent fee basis.
GeneDx (WGS) Valuation After New Clinical Breakthroughs Spotlighted Ahead of 2025 NSGC Conference
GeneDx Holdings is gaining attention for its upcoming presentations at the 2025 National Society of Genetic Counselors Annual Meeting, focusing on advancements in rare disease diagnosis. The company's stock has seen significant growth, with a 14.9% 1-month share price return and an 81.9% total shareholder return over the past year, prompting discussions about its valuation. While narratives suggest a 7.5% undervaluation, a DCF model indicates shares might be trading 44.8% below fair value.
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
Schubert Jonckheer & Kolbe LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) for potential legal claims related to allegations that the company misled investors about its health intelligence platform, Centrellis. A U.S. District Judge has allowed a securities fraud lawsuit to proceed, alleging GeneDx overstated Centris's capabilities and commercial viability, leading to artificially inflated stock prices. The firm encourages current shareholders of GeneDx to contact them regarding possible legal options.
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by officers and directors of GeneDx Holdings Corp. to its shareholders. Shareholders who acquired WGS stock on or before January 18, 2022, are encouraged to contact the firm to discuss their legal rights and options, which may include corporate governance reforms or financial relief. The firm offers to handle the action on a contingent fee basis, emphasizing that shareholder involvement can enhance company transparency and value.
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot - MarketScreener
Illumina's new constellation mapped read technology is being piloted by GeneDx to uncover difficult-to-detect genomic insights in rare diseases. Early results demonstrate the technology's accuracy and speed in identifying challenging variants, outperforming traditional methods. This innovation holds promise for advancing diagnosis and treatment in complex genetic conditions and is expected to be commercially available in early 2026.
GeneDx Q2 2025 presentation: revenue jumps 49%, guidance raised on strong results - Investing.com Canada
This article headline reports that GeneDx experienced a significant 49% increase in revenue for Q2 2025. The company has subsequently raised its financial guidance due to these strong results, as detailed in its presentation.
Earnings call transcript: GeneDx Q2 2025 shows strong revenue growth By Investing.com - Investing.com Canada
The article reports an application error encountered while attempting to load content from ca.investing.com regarding GeneDx's Q2 2025 earnings call transcript. This error prevented the display of the earnings report which was anticipated to show strong revenue growth for GeneDx.
Legal Advantage Investments Inc. Boosts Holdings in GeneDx Holdings Corp. $WGS
Legal Advantage Investments Inc. significantly increased its stake in GeneDx Holdings Corp. by nearly 20%, now owning 60,600 shares valued at approximately $5.6 million. This makes GeneDx the firm's 12th largest holding, alongside other institutional investors who have also acquired positions. However, the article also notes significant insider selling, with CEO Katherine Stueland and Director Casdin Capital selling substantial amounts of shares.
GeneDx Holdings Appoints Thomas Fuchs to Board
GeneDx Holdings has appointed Thomas Fuchs, SVP and Chief AI Officer at Eli Lilly and Company, as a Class I director to its Board, expanding it to eight members. Dr. Fuchs's expertise in artificial intelligence and machine learning is expected to enhance GeneDx’s strategic direction. GeneDx Holdings (WGS) currently holds a Neutral rating from Spark, TipRanks’ AI Analyst, due to strong financial performance offset by a high P/E ratio and overbought technical conditions.
How Raised 2025 Guidance and Research Advances at GeneDx Holdings (WGS) Have Changed Its Investment Story
GeneDx Holdings (WGS) recently raised its full-year 2025 revenue guidance and reported strong Q3 results, highlighting accelerated clinical adoption for its precision genomics. The company also announced new genetic research findings, which could bolster product differentiation and reinforce reimbursement rates. While revenue growth and clinical adoption are key short-term catalysts, the long-term investment narrative heavily depends on evolving insurance reimbursement practices and payer policies.
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
The Rosen Law Firm is investigating potential securities claims on behalf of GeneDx Holdings Corp. (NASDAQ: WGS) investors following a report by Grizzly Research alleging widespread fraud and exploitation of Medicaid and Medicare systems to inflate revenue. The firm is preparing a class action lawsuit to recover investor losses after GeneDx's stock fell in response to these allegations. Investors are encouraged to contact the law firm for more information.
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
The Rosen Law Firm is investigating potential securities claims against GeneDx Holdings Corp. (NASDAQ: WGS) following a Grizzly Research report alleging fraudulent schemes to inflate revenue. The report, published on February 5, 2025, led to a 6.7% stock drop for GeneDx. The firm is preparing a class action lawsuit to recover investor losses and encourages affected shareholders to join the prospective action.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
Rosen Law Firm is investigating potential securities claims against GeneDx Holdings Corp. (NASDAQ: WGS) following allegations of widespread fraud that caused a significant drop in stock price. The firm is encouraging investors who purchased GeneDx securities to join a prospective class action to recover losses. This investigation comes after a report by Grizzly Research claimed GeneDx's growth was driven by fraudulent schemes exploiting Medicaid and Medicare systems.
GeneDx Holdings Corp. Executives Sell Shares for Tax Obligations
GeneDx Holdings Corp. executives, Katherine Stueland (CEO) and Kevin Feeley (CFO), recently sold shares of the company's Class A Common Stock. These sales were conducted to cover tax withholding obligations arising from the vesting of restricted stock units. Following these transactions, both executives retain significant holdings in the company, including direct ownership, restricted stock units, and stock options.
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
GeneDx Holdings Corp. announced robust financial results for the second quarter of 2025, reporting revenues of $102.7 million, a 49% increase year-over-year, and an adjusted net income of $15.0 million. The company raised its full-year 2025 revenue guidance to $400-$415 million and highlighted key strategic achievements, including the American Academy of Pediatrics' recommendation for exome and genome testing as a first-line diagnostic for certain pediatric conditions. GeneDx also detailed its expanded market access, clinical innovations, and the acquisition of Fabric Genomics.
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims on behalf of GeneDx Holdings Corp. (NASDAQ: WGS) shareholders due to allegations of materially misleading business information. A February 2025 report from Grizzly Research accused GeneDx of "widespread fraud" and exploiting Medicaid and Medicare systems to inflate revenue, causing a significant drop in its stock price. The firm encourages affected investors to join a prospective class-action lawsuit to recover losses.
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Alert: Schubert Jonckheer Investigates Possible False Statements and Insider Trading
Schubert Jonckheer & Kolbe LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) for potential false statements and insider trading related to its health intelligence platform, Centrellis. A securities fraud lawsuit has been allowed to proceed, alleging that GeneDx overstated Centrellis's capabilities between January and August 2022, leading to artificially inflated stock prices and subsequent insider stock sales. When the truth emerged about strategic shifts and workforce reductions, GeneDx's stock price fell by 33%.
GeneDx Reports First Quarter 2025 Financial Results and Business Highlights
GeneDx reported strong first-quarter 2025 financial results, with revenues reaching $87.1 million, a 42% year-over-year increase, and exome and genome test revenue growing by 62%. The company achieved its third consecutive quarter of profitability with an adjusted net income of $7.7 million and updated its full-year 2025 revenue guidance to $360 to $375 million, driven by core momentum, outpatient expansion, and strategic initiatives like the planned acquisition of Fabric Genomics. Key business highlights include the launch of ultraRapid Whole Genome Sequencing and Epic Aura, expansion of testing indications for cerebral palsy and Inborn Errors of Immunity, and advancement in AI-powered genetic analysis with Multiscore.
GeneDx Holdings Corp. Executives Sell Shares for Tax Obligations
GeneDx Holdings Corp. executives, including CEO Katherine Stueland and CFO Kevin Feeley, recently sold shares of the company's Class A Common Stock. These sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units. Stueland sold 1,657 shares for $130,045, and Feeley sold 275 shares for $21,582.
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
GeneDx achieved profitability in Q3 2024 with a $1.2M adjusted net income and reported revenues of $76.6M, representing 77% year-over-year growth in exome and genome test revenue. The company raised its full-year 2024 revenue guidance to between $284M and $290M and highlighted significant advancements in genomic testing, including expanded Medicaid coverage and leadership in genomic newborn screening.
StockWatch: Turnaround Lifts GeneDx Stock 3,600%, with Profitability Near
GeneDx has seen its stock skyrocket over 3,600% since November due to a successful pivot to whole exome and whole genome sequencing for rare pediatric diseases. The company reported strong Q2 results with significant revenue growth and adjusted gross margins, reiterating its plan to achieve profitability in 2025. Analysts have largely approved of the strategic refocus, with some predicting profitability even sooner than forecast.
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
Sema4 Holdings Corp. has officially changed its name to GeneDx Holdings Corp. and will trade under the new Nasdaq ticker "WGS" starting January 10, 2023. The company also reported preliminary 2022 financial results, exceeding revenue targets, and provided 2023 guidance, anticipating continued growth and a path to profitability by 2025. GeneDx aims to lead in genomic and clinical insights by leveraging its exome and genome testing with the Centrellis® platform to advance precision medicine.
